Octreoscan is a drug owned by Curium Us Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 26, 2017. Details of Octreoscan's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6123916 | Therapeutic use of somatostatin peptides |
Sep, 2017
(7 years ago) |
Expired
|
| US5776894 | Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors |
Jul, 2015
(9 years ago) |
Expired
|
| US5753627 | Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis |
May, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Octreoscan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Octreoscan's family patents as well as insights into ongoing legal events on those patents.
Octreoscan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Octreoscan's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 26, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Octreoscan Generic API suppliers:
Indium In-111 Pentetreotide Kit is the generic name for the brand Octreoscan. 1 company has already filed for the generic of Octreoscan. Check out the entire list of companies who have already received approval for Octreoscan's generic
About Octreoscan
Octreoscan is a drug owned by Curium Us Llc. It is used for detecting neuroendocrine tumors. Octreoscan uses Indium In-111 Pentetreotide Kit as an active ingredient. Octreoscan was launched by Curium in 1994.
Approval Date:
Octreoscan was approved by FDA for market use on 02 June, 1994.
Active Ingredient:
Octreoscan uses Indium In-111 Pentetreotide Kit as the active ingredient. Check out other Drugs and Companies using Indium In-111 Pentetreotide Kit ingredient
Treatment:
Octreoscan is used for detecting neuroendocrine tumors.
Dosage:
Octreoscan is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3mCi/ML | INJECTABLE | Prescription | INJECTION |